The efficacy of combined topical niosomal dapsone gel and intralesional injection of meglumine antimoniate in comparison with intralesional meglumine antimoniate and cryotherapy in the treatment of cutaneous leishmaniasis
Keywords:
Leishmaniasis, dapsone, niosomal, topical, treatmentAbstract
Objective To evaluate the efficacy of niosomal dapsone gel and intralesional meglumine antimoniate with cryotherapy and intralesional meglumine antimoniate in cutaneous leishmaniasis. Methods This was a randomized clinical trial with 73 participants that were divided into two groups including, case group (weekly intralesional meglumine antimoniate and twice a day niosomal dapsone gel) and control group (weekly intralesional meglumine antimoniate with biweekly cryotherapy). The treatment course continued until 16 weeks or complete cure, whatever occurred earlier and participants were followed up in 4th, 8th, 12th and 16th weeks of the treatment. Results Overall, 68 patients (33 males and 35 female) completed the study. Age, sex, size and duration of the lesions were not statistically different between two groups. At the end of the study, 82.9% of patients in case group showed complete response. Conclusion Niosomal dapsone gel has promising results with fewer adverse effects, so, it can be used as an alternative treatment modality, especially in children and patients with contraindication of systemic drugs.References
Ramtin Hadighi R, Mehdi Mohebali M, Patrick Boucher P, Homa Hajjaran H, Ali Khamesipour A, Marc Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006;3:e162.
Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001;95:239-43.
William H, Markle MD, Khaldoun M. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician. 2004;69:1455-60.
Al-Jaser M, el-Yazigi A, Kojan M, croft SL. Distribution and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents Chemother. 1995;39:516-9.
Jeronimo SB, Sousa A, Pearson RD. Leishmaniasis species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Churchill-Livingstone 2005; 45-65.
Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol. 1996;14:425-31.
Mohajery M, Bolursaz M, Shamsian S. A survey on the prevalence of cutaneous leishmaniasis in the students of Mashhad district. J Mashhad Faculty Med. 2001;44(72):54-60.
Azizi F, Hatam H, Janghorbani M. Epidemiology and control of common disorders in Iran. Tehran: Khosravi Publications 2003. P. 524-32.
Athari A, Jalalloo N. Epidemiology of five year of cutaneous leishmaniasis in Iran (2001-2005). Isfahan Faculty Med J. 2006;24:8-13.
Vardy D, Barenholz Y, Cohen R, Zvulunov A, Biton A, Klaus S. Topical amphotericin B for cutaneous leishmaniasis. Arch Dermatol. 1999;135:856-7.
Al-Jaser MH. Treatment trends of cutaneous leishmaniasis in Saudi Arabia. Saudi Med J. 2005;26:1220-4.
Akilov OE, Kosaka B. Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis in direct and mediated through the killing of host cell. Exp Dermatol. 2007;16:651-60.
Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1991;85:212-3.
Esfandiarpour I, Alavi AF. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol. 1997;36:59-60.
Shamsi Meimandi S, Zandi S, Dabiri SH. Efficacy of topical 5% imiquimod with cryotherapy versus intralesional meglumine antimoniate in treatment of anthroponotic cutaneous leishmaniasis. Iran J Dermatol. 2001;14:42-47.
Magill AJ. Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am. 2005;19:241-66.
Dogra J, Lal BB, Misra SN. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol. 1986;25:398-400.
Al-Mutairi N, Alshiltawy M, El Khalawany M, Joshi A, Eassa BI, Manchanda Y et al. Tropical medicine rounds: Treatment of old world cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy and imiquimod alone and in combination. Int J Dermatol. 2009;48:862-9.
Zhu, Y.I. and M.J. Stiller, Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420-34.
Raimer S, Maloney JM, Bourcier M, Wilson D. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis. 2008;81:171-8.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111-26.
Faghihi G, Tavakoli‐kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol. 2003;28:13-6.
Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol. 2005;15:85-7.
Alavi-Naini R, Fazaeli A, O’Dempsey T. Topical treatment modalities for old world cutaneous leishmaniasis: a review. Prague Med Report. 2012;113:105-18.
Draelos ZD, Carter E, Maloney M. Two randomized studies demonstrate the efficacy and safety of dapsone gel 5%, for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439.e1-10.
Lucky AW, Roberts J, Maloney M, Ling M. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol. 2007;6:981-7.
Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol. 2007;57:335. e1-29. E.
Munir A, Janjua SA, Hussain I. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerologica Croatica. 2008;16(2):60-4.
Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43:281-3.
Nilforooshzadeh MA, Jaffari F, Malekafzali B. Efficacy of combined triple therapy (paromomycin ointment, cryotherapy and intralesional Glucantime) in comparison with intralesional Glucantime for the treatment of acute cutaneous leishmaniasis. Iran J Dermatol. 2004;7:136-9.
Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol. 2003;97:493-8.
Layegh P, Rajabi O, Jafari MR, Emamgholi Tabar Malekshah P, Moghiman T, Ashraf H et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res. 2011;2011:523-656.
Larbi EB, al-Khawajah A, al-Gindan Y, Jain S, Abahusain A, al-Zayer A. A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg. 1995;52:166-8.
El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study. J Am Acad Dermatol. 1992;27:227-31.
Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol. 2006;31:634-7.
Carneiro G, Santos DC, Oliveira MC, Fernandes AP, Ferreira LS, Ramaldes GA et al. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res. 2010;20:16-23.
Asadi AP, Moshafi M, I Sharifi M. Preparation and in vivo administration of paromomycin niosomes in balb/c mice. Res Pharm Sci. 2012;7:S373.
Wadher, S, Puranik MP, Karande NA, Yeole PG. Synthesis and biological evaluation of Schiff base of dapsone and their derivative as antimicrobial agents. Int J Pharm Tech Res. 2009;1:22-33.
Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin. 2001;19:79-86.
Ji B, Perani EG, Petinom C, N'Deli L, Grosset JH. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother. 1994;38:662-7.
Raeiszadeh M. Preparation and characterization of dapsone-loaded niosomal gel for local treatment of cutaneous leishmaniasis. Kerman, Iran: School of Pharmacy, Kerman University of Medical Sciences; 2012.
Manconi M, Sinico C, Valenti D, Lai F, Fadda AM. Niosomes as carriers for tretinoin: III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm. 2006;311:11-9.
Fazaeli A, Fouladi B, Sharifi I. Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey. J Vector Borne Dis. 2009;46:36-42.
